Francis Price is an Ophthalmology physician affiliated with Price Vision Group. OpenAlex indexes 368 publications with 18,209 citations (h-index 74); ClinicalTrials.gov lists 16 registered studies matched to this name. By OpenAlex citation count, this profile ranks in the top 5% of Ophthalmology profiles in the findmyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingClinical trials
- Loteprednol Etabonate 0.25% for Prevention of Cornea Transplant Rejection
Sponsor: Price Vision Group
- Corneal Crosslinking for Treatment of Corneal Neovascularization
Sponsor: Price Vision Group
- Effect of Xen Implantation on the Aqueous Humor Proteome
Sponsor: Price Vision Group
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
4 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
4 companies with payments on record in CMS Open Payments (2021 onward), matched to this physician's NPI. The itemized breakdown by company, amount and year is part of the full profile. Why? →
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Sensory organs
69%Corticosteroid35.9%Prednisolone Acetate63%Fluorometholone37%Part D≥326 patientsQuinolone Antimicrobial13.3%Ofloxacin100%Part D≥251 patients+ 7 more classes in this area
Musculoskeletal
17.1%Nonsteroidal Anti-inflammatory Drug9.9%Diclofenac Sodium100%Part D≥224 patientsCyclooxygenase Inhibitor7.2%Ketorolac Tromethamine100%Part D≥160 patientsAnti-infectives
9.2%First-generation cephalosporins7.2%Cephalexin100%Part D≥143 patientsHerpesvirus Nucleoside Analog DNA Polymerase Inhibitor1.1%Valacyclovir100%Part D≥15 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”